NCT03884192Unknown3 期
CONSIST: A Phase III Randomized Control Study of Consolidation Sintilimab (IBI308) After Concurrent Chemoradiation Versus Chemoradiation Alone in Patients With Unresectable Local Advanced Stage III NSCLC
Shandong Cancer Hospital and Institute1 个研究点 分布在 1 个国家目标入组 162 人开始时间: 2018年12月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 162
- 试验地点
- 1
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
This is an open label, multi-center, randomized, control phase III trial, to compare the efficacy and safety of consolidation therapy with sintilimab (IBI308) versus best supported care (BSC), in unresectable stage III NSCLC patients who do not experience disease progression after initial concurrent chemoradiation.
详细描述
This is an open label, multi-center, randomized, control study of sintilimab versus BSC in unresectable local advanced stage III NSCLC patients without disease progression after concurrent chemoradiation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent before initiation of any study procedures
- •Age ≥ 18 years and ≤ 75 years
- •Histologically or cytologically confirmed NSCLC, with unresectable local advanced disease (stage III according to NSCLC staging version 8)
- •Expected survival over 3 months
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •At least 1 measurable disease according to RECIST 1.1
- •Pulmonary function: forced expiratory volume at one second (FEV1) > 1 liter(L)
- •Patient must not have received any anti-cancer therapy for the purpose of treating lung cancer. However, exploratory thoracotomy, mediastinoscopy, excision biopsy, and other kinds of surgery for diagnosis and staging purpose is acceptable. Patients with local or regional recurrent disease after pneumonectomy is allowed to participate if they meet other inclusion criteria (e.g. stage III, inappropriate for re-operation).
- •For all female patients of childbearing potential, a negative pregnancy test (either urine or serum) must be obtained within 3 days before the first dose (Cycle 1, Day 1) of study treatment. If a urine pregnancy test shows an unconfirmed result, a serum pregnancy test must be performed.
- •Adequate hematopoietic function, defined as: absolute neutrophil count (ANC) ≥ 1.5 x 10*9/L; platelet count ≥100 x 10*9/L; hemoglobin ≥90 g/L [no blood transfusion within 7 days or not erythropoietin (EPO) dependent]
- •Adequate liver function, defined as: total serum bilirubin ≤ 1.5 x upper limit of normal (ULN); serum alanine transaminase (ALT) and aspartic transaminase (AST) ≤ 2.5 x ULN, with no liver transplantation
- •Adequate renal function, defined as: serum creatinine ≤ 1.5 x ULN or calculated creatinine-clearance ≥ 60 ml/min (Cockcroft-Gault). Urine protein less than 2+ by urinalysis or 24-hour urinary protein quantity < 1g
- •Adequate coagulation function, defined as: international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN. For patients receiving anticoagulant therapy can be enrolled if PT is within the range defined by anticoagulant therapy.
- •Myocardial enzymes are within normal range
- •All subjects of childbearing potential must agree to use efficient contraceptive methods that result in a failure rate of < 1% per year during the study treatment period and for at least 180 days after discontinuation from study treatment.
排除标准
- •Being treated by other investigational drugs within an interventional study, or have received any investigational drugs or instruments within 4 weeks prior to the first dose of study treatment
- •Being enrolled in other interventional studies, unless they are observational studies or during the follow-up stage of an interventional study
- •NSCLC histology with small cell lung cancer (SCLC) components
- •Active or autoimmune disease history (within the past 2 years), or history of immune deficiency
- •Previous immune therapy including: anti PD-1, anti PD-L1, anti PD-L2 or treatment targeting other co-stimulatory or co-inhibitory T-cell receptors [e.g. cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, and CD137]
- •a) Systemic therapy with Chinese patent medicine or drugs of immunoregulation effect (including thymosin, interferon, interleukin, unless local delivery for controlling pleural effusion) within 2 weeks prior to the first dose of study treatment, or major surgery within 4 weeks prior to the first dose of study treatment
- •Clinical evidence of active diverticulitis, abdominal abscess, or gastrointestinal obstruction
- •Previous organ or blood system transplantation
- •Known allergic to pemetrexed, paclitaxel, etoposide, cisplatin, carboplatin, sintilimab component and/or any excipients
- •A history of active autoimmune disease requiring systemic treatment (e.g. using drugs for disease remission, corticosteroids or immunosuppressor) within 2 years prior to the first dose of study treatment. Substitution therapy (e.g. thyroxine, insulin or physiological corticosteroids for treating adrenal or pituitary dysfunction) is not considered as a systemic treatment.
- •a) Diagnosis as immunodeficiency, or being treated with systemic glucocorticoid or other kinds of immunosuppressor within 7 days prior to the first dose of study treatment. A physiological dose of glucocorticoid (≤10 mg/day prednisone or equivalent dose of other steroids) is permitted.
- •Previously diagnosis as other malignant tumors within 5 years prior to the first dose of study treatment, with the exception of: skin basal cell carcinoma or squamous cell carcinoma with radical treatment, and/or carcinoma in situ underwent radical resection
- •History of non-infectious pneumonitis requiring treatment with glucocorticoid within 1 year prior to the first dose of study treatment, or currently existed interstitial lung disease
- •Active infectious that required systemic therapy
- •Know psychiatric illness or drug abuse that would limit compliance with study requirements
- •Know human immunodeficiency virus (HIV) infection (HIV 1/2 antibody positive)
- •Untreated active viral hepatitis B (HBV)
- •Patients with HBV who meet the following criteria are also eligible:
- •HBV virus load (VL) <1000 copy/ml (200 IU/ml), and patients must continuously receive anti-HBV therapy during all through study treatment phase to prevent virus activation
- •Patients with a result of anti-HBc(+)、HBsAg (-)、anti-HBs (-) 和 HBV VL (-) are not required to receive prophylactic anti-HBV therapy, but must be closely monitored for virus re-activation
- •Patients with active HCV infection (HCV antibody positive and HCV-RNA > the lower detection limit)
- •History or evidence of disease, treatment or laboratory abnormalities that would interfere the study outcome, prevent patients from participating entirely, or ineligible to enroll per the investigators' judgement
- •Pregnant or lactating women
研究组 & 干预措施
Sintilimab Arm
Experimental
Sintilimab consolidation therapy
干预措施: Consolidation Sintilimab (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: up to 24 months after enrollment or study close
PFS (per RECIST 1.1 as assessed by the investigator) will be defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression).
次要结局
- Overall survival (OS)(up to 24 months after enrollment or study close)
- Objective Response Rate (ORR)(up to 24 months after enrollment or study close)
- Disease Control Rate (DCR)(up to 24 months after enrollment or study close)
- Duration of Response (DoR)(up to 24 months after enrollment or study close)
- Progression Free Survival (PFS) Rate at 12/18 months(From the date of randomization until the Kaplan-Meier estimate of PFS at 12/18months)
- Treatment-related Adverse Events (AEs)(From the date of randomization to 90 days after last dose of study treatment)
研究者
Jinming Yu
President of Shandong Cancer Hospital and Institute
Shandong Cancer Hospital and Institute
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell CancerPrimary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1NCT04394975Shanghai Junshi Bioscience Co., Ltd.421
进行中（未招募）
3 期
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)Triple-Negative Breast CancerNCT06382142Sichuan Baili Pharmaceutical Co., Ltd.418
已完成
3 期
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)Relapsed Follicular LymphomaNCT01827605Fondazione Italiana Linfomi - ETS159
进行中（未招募）
3 期
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)Small Cell Lung CancerNCT06500026Sichuan Baili Pharmaceutical Co., Ltd.722
进行中（未招募）
3 期
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)Non-small Cell Lung CancerNCT06382129Sichuan Baili Pharmaceutical Co., Ltd.698